Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lyell Immunopharma (LYEL) Return on Assets (2021 - 2025)

Lyell Immunopharma's Return on Assets history spans 5 years, with the latest figure at 0.83% for Q3 2025.

  • For Q3 2025, Return on Assets fell 53.0% year-over-year to 0.83%; the TTM value through Sep 2025 reached 0.83%, down 53.0%, while the annual FY2024 figure was 0.54%, 27.0% down from the prior year.
  • Return on Assets for Q3 2025 was 0.83% at Lyell Immunopharma, roughly flat from 0.83% in the prior quarter.
  • Across five years, Return on Assets topped out at 0.14% in Q3 2021 and bottomed at 0.83% in Q2 2025.
  • The 5-year median for Return on Assets is 0.23% (2023), against an average of 0.35%.
  • The largest annual shift saw Return on Assets increased 2bps in 2023 before it tumbled -53bps in 2025.
  • A 5-year view of Return on Assets shows it stood at 0.18% in 2021, then dropped by -2bps to 0.19% in 2022, then plummeted by -54bps to 0.29% in 2023, then tumbled by -108bps to 0.6% in 2024, then plummeted by -37bps to 0.83% in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Return on Assets are 0.83% (Q3 2025), 0.83% (Q2 2025), and 0.74% (Q1 2025).